Clinical Trials Logo

Light Chain Deposition Disease clinical trials

View clinical trials related to Light Chain Deposition Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05283993 Recruiting - Multiple Myeloma Clinical Trials

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Start date: July 1, 2021
Phase:
Study type: Observational

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

NCT ID: NCT03820817 Recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Rifaximin in Patients With Monoclonal Gammopathy

Start date: May 15, 2019
Phase: Phase 1
Study type: Interventional

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

NCT ID: NCT03717844 Recruiting - Multiple Myeloma Clinical Trials

Registry for Adults With Plasma Cell Disorders (PCD's)

Start date: February 9, 2018
Phase:
Study type: Observational [Patient Registry]

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).